|
08 Sep 2020 |
AVEO Oncology Regains Full Global Rights to Ficlatuzumab
|
|
08 Sep 2020 |
Atara Biotherapeutics Announces FDA Clearance of IND for ATA2271, a Next-Generation Autologous Mesothelin-Targeted CAR T with Novel PD1DNR and 1XX Technologies Combined to Treat Solid Tumors
|
|
08 Sep 2020 |
Caribou Biosciences Announces FDA Clearance of its IND for CB-010, an Off-the-shelf Allogeneic Anti-CD19 CAR-T Cell Therapy
|
|
08 Sep 2020 |
Goldfinch Bio Initiates Phase 2 Clinical Trial Evaluating Novel Drug Candidate GFB-887 as a Precision Medicine for Patients with Kidney Diseases
|
|
08 Sep 2020 |
Exelixis and Catalent Enter into Collaboration, License, and Exclusive Option Agreement to Develop Antibody-Drug Conjugates Leveraging SMARTag® Bioconjugation Technology
|
|
08 Sep 2020 |
Exelixis and NBE-Therapeutics Enter Into Exclusive Collaboration and License Option Agreement to Discover and Develop Novel Antibody-Drug Conjugates for the Treatment of Cancer
|
|
08 Sep 2020 |
Liminal BioSciences Announces Resubmission of Biologics License Application to U.S. Food and Drug Administration for Ryplazim® (plasminogen)
|
|
08 Sep 2020 |
Merck’s Gefapixant (45 mg Twice Daily) Significantly Decreased Cough Frequency Compared to Placebo at Week 12 and 24 in Patients with Refractory or Unexplained Chronic Cough
|
|
08 Sep 2020 |
SpyBiotech and Serum Institute of India announce that the first subjects have been dosed in a Phase I/II trial of a novel virus-like particle vaccine targeting COVID-19
|
|
08 Sep 2020 |
Zion Pharma Announces Initiation of Phase 1 Study
|
|
08 Sep 2020 |
Intravacc Receives US NIH/NIAID Contract to Develop Enterovirus D68 Vaccine
|
|
08 Sep 2020 |
Valneva Initiates Phase 3 Clinical Study for its Chikungunya Vaccine Candidate VLA1553
|
|
07 Sep 2020 |
Janssen Announces European Commission Decision for Expanded Use of IMBRUVICA® (ibrutinib) in Combination with Rituximab for Previously Untreated Patients with Chronic Lymphocytic Leukaemia (CLL)
|
|
07 Sep 2020 |
IcanoMAB GmbH Founded with Private Funding to Develop Precision Canonical Monoclonal Antibodies in Oncology, Immune-Modulation, Acute Inflammation and Most Urgently for Covid-19
|
|
07 Sep 2020 |
Grifols to acquire Alkahest to enhance discovery research and development to identify innovative therapies for age-related diseases based upon an understanding of the human plasma proteome
|
|
07 Sep 2020 |
Boehringer Ingelheim Discontinues Development of BI 1467335 for Diabetic Retinopathy
|
|
05 Sep 2020 |
Lexicon Pharmaceuticals Announces Commencement of Patient Dosing in RELIEF-DPN-1 Phase 2 Clinical Study of LX9211 in Patients With Diabetic Peripheral Neuropathic Pain
|
|
05 Sep 2020 |
Arcturus Therapeutics Announces Preclinical Publication of its COVID-19 Vaccine Candidate
|
|
05 Sep 2020 |
Kite Submits Supplemental Biologics License Application to U.S. Food and Drug Administration for Yescarta® in Relapsed or Refractory Indolent Non-Hodgkin Lymphomas
|
|
05 Sep 2020 |
AbbVie and I-Mab Enter Into Global Strategic Partnership for Differentiated Immuno-oncology Therapy
|
